CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK [Yahoo! Finance]
CureVac N.V. - Ordinary Shares (CVAC)
Company Research
Source: Yahoo! Finance
Study initiated following previously reported interim data from Phase 2 Part of combined Phase 1/2 study in seasonal influenza Composition of vaccine candidate changed to match all three WHO-recommended flu strains, following recommendation to exclude B/Yamagata lineage TÜBINGEN, GERMANY AND BOSTON, MA / ACCESSWIRE / May 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced dosing of the first participant in a Phase 2 study of the multivalent seasonal influenza vaccine candidate developed in collaboration with GSK. The study will assess targeted optimizations for improved immune responses of the vaccine candidate against the relevant influenza B strain. This new Phase 2 study in the joint CureVac/GSK seasonal influenza program has been initiated following interim data from the Phase 2 part of the ongoing combined Phase 1/2 study in sea
Show less
Read more
Impact Snapshot
Event Time:
CVAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVAC alerts
High impacting CureVac N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
CVAC
News
- CureVac Announces Voting Results of General MeetingAccesswire
- CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSKAccesswire
- CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update Accesswire
- Human Bird Flu Cases Spur Retail Trader Rush Into Vaccine Stocks [Yahoo! Finance]Yahoo! Finance
- CureVac (NASDAQ: CVAC) was downgraded by analysts at Leerink Partnrs from an "outperform" rating to a "market perform" rating.MarketBeat
CVAC
Sec Filings
- 6/24/24 - Form 6-K
- 5/28/24 - Form 6-K
- 5/24/24 - Form 6-K
- CVAC's page on the SEC website